Concise review: Preleukemic stem cells: Molecular biology and clinical implications of the Precursors to leukemia stem cells

Stem Cells Translational Medicine

Volumn 2, Issue 2, 2013, Pages 143-150

  Pandolfi, Ashley ^a   Barreyro, Laura ^a   Steidl, Ulrich ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acute myelogenous leukemia; Cancer stem cells; Hematopoietic stem cells; Stem progenitor cell

Indexed keywords

CD135 ANTIGEN; CYCLINE; INTERLEUKIN 1 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR PU 1; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMOTHERAPY; DEATH; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HEMATOPOIETIC STEM CELL; HOMEOBOX; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NONHUMAN; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; STEM CELL EXPANSION;

EID: 84876511698     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0109     Document Type: Review

References (104)

1. Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cell 2002;1:417-420.
2. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-743.
3. Friedman AD. Transcriptional control of granulocyte and monocyte development. Oncogene 2007;26:6816-6828.
4. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol 2006;24:705-738.
5. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101.
6. Shih LY, Liang DC, Huang CF et al. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: A comparative analysis on paired diagnosis and relapse samples. Leukemia 2006;20:604-609.
7. Tiesmeier J, Czwalinna A, Muller-Tidow C et al. Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. Br J Haematol 2003;123:413-419.
8. Kirstetter P, Schuster MB, Bereshchenko O et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 2008;13:299-310.
9. Bereshchenko O, Mancini E, Moore S et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell 2009;16:390-400.
10. de Guzman CG, Warren AJ, Zhang Z et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 2002;22:5506-5517.
11. Chen W, Kumar AR, Hudson WA et al. Malignant transformation initiated by Mll-AF9: Gene dosage and critical target cells. Cancer Cell 2008;13:432-440.
12. Kuo YH, Landrette SF, Heilman SA et al. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell 2006;9:57-68.
13. Rosenbauer F, Wagner K, Kutok JL et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, Pu 1. Nat Genet 2004;36:624-630.
14. Passegué E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004;119:431-443.
15. Santaguida M, Schepers K, King B et al. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell 2009;15:341-352.
16. Shimizu R, Kuroha T, Ohneda O et al. Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol 2004;24:10814-10825.
17. Steidl U, Rosenbauer F, Verhaak RG et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 2006;38:1269-1277.
18. Kawahara M, Pandolfi A, Bartholdy B et al. H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell 2012;22:194-208.
19. Orkin SH, Zon LI. Hematopoiesis: An evolving paradigm for stem cell biology. Cell 2008;132:631-644.
20. Khandanpour C, Kosan C, Gaudreau MC et al. Growth factor independence 1 protects hematopoietic stem cells against apoptosis but also prevents the development of a myeloproliferative-like disease. STEM CELLS 2011;29:376-385.
21. Smith LL, Yeung J, Zeisig BB et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011;8: 649-662.
22. Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 2002;109:39-45.
23. Ruiz-Herguido C, Guiu J, D'Altri T et al. Hematopoietic stem cell development requires transient Wnt/beta-catenin activity. J Exp Med 2012;209:1457-1468.
24. Rodrigues NP, Tipping AJ, Wang Z et al. GATA-2 mediated regulation of normal hematopoietic stem/progenitor cell function, myelodysplasia and myeloid leukemia. Int J Biochem Cell Biol 2012;44:457-460.
25. Akala OO, Clarke MF. Hematopoietic stem cell self-renewal. Curr Opin Genet Dev 2006;16:496-501.
26. Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood 2008;111:492-503.
27. Wang J, Han F, Wu J et al. The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood 2011;118:5429-5438.
28. Wu JQ, Seay M, Schulz VP et al. Tcf7 is an important regulator of the switch of self-renewal and differentiation in a multipotential hematopoietic cell line. PLoS Genet 2012;8: e1002565.
29. Ooi SK, O'Donnell AH, Bestor TH. Mammalian cytosine methylation at a glance. J Cell Sci 2009;122:2787-2791.
30. Illingworth RS, Bird AP. CpG islands: "A rough guide." FEBS Lett 2009;583:1713-1720.
31. Ji H, Ehrlich LI, Seita J et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010;467:338-342.
32. Bocker MT, Hellwig I, Breiling A et al. Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood 2011;117:e182-e189.
33. Bröske AM, Vockentanz L, Kharazi S et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 2009;41:1207-1215.
34. Trowbridge JJ, Snow JW, Kim J et al. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 2009;5:442-449.
35. Figueroa ME, Lugthart S, Li Y et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17:13-27.
36. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-567.
37. Akalin A, Garrett-Bakelman FE, Kormaksson M et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 2012;8:e1002781.
38. Zhou L, Opalinska J, Sohal D et al. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem 2011;286:25211-25223.
39. Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-2433.
40. Yan XJ, Xu J, Gu ZH et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011;43:309-315.
41. Hollink IH, Feng Q, Danen-van Oorschot AA et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia 2012;26:371-373.
42. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066.
43. Tanaka S, Miyagi S, Sashida G et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012;120:1107-1117.
44. Ko M, Huang Y, Jankowska AM et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843.
45. Chou WC, Chou SC, Liu CY et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011;118:3803-3810.
46. Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-842.
47. Tefferi A, Lim KH, Abdel-Wahab O et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-1345.
48. Couronné L, Lippert E, Andrieux J et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010;24:201-203.
49. Kosmider O, Gelsi-Boyer V, Ciudad M et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009;94:1676-1681.
50. Pratcorona M, Abbas S, Sanders MA et al. Acquired mutations in ASXL1 in acute myeloid leukemia: Prevalence and prognostic value. Haematologica 2012;97:388-392.
51. Abdel-Wahab O, Mullally A, Hedvat C et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-147.
52. Paschka P, Schlenk RF, Gaidzik VI et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636-3643.
53. Schnittger S, Haferlach C, Ulke M et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010;116:5486-5496.
54. Challen GA, Sun D, Jeong M et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011;44:23-31.
55. Moran-Crusio K, Reavie L, Shih A et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011;20:11-24.
56. Sasaki M, Knobbe CB, Munger JC et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012;488:656-659.
57. Abdel-Wahab O, Adli M, Lafave LM et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012;22:180-193.
58. Harris WJ, Huang X, Lynch JT et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012;21:473-487.
59. Gan B, Hu J, Jiang S et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010;468: 701-704.
60. Zhang J, Grindley JC, Yin T et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006;441:518-522.
61. Iriuchishima H, Takubo K, Matsuoka S et al. Ex vivo maintenance of hematopoietic stem cells by quiescence induction through Fbxw7 overexpression. Blood 2011;117:2373-2377.
62. Grignani F, Valtieri M, Gabbianelli M et al. PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000;96:1531-1537.
63. Ito K, Bernardi R, Morotti A et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072-1078.
64. Chen C, Liu Y, Liu R et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008;205:2397-2408.
65. Takubo K, Goda N, Yamada W et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 2010; 7:391-402.
66. Gurumurthy S, Xie SZ, Alagesan B et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010;468: 659-663.
67. Nakada D, Saunders TL, Morrison SJ. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 2010;468:653-658.
68. Cozzio A, Passegue E, Ayton PM et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17:3029-3035.
69. Huntly BJ, Shigematsu H, Deguchi K et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6:587-596.
70. Passegué E, Jochum W, Schorpp-Kistner M et al. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001;104:21-32.
71. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006;10:257-268.
72. Krivtsov AV, Twomey D, Feng Z et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006;442:818-822.
73. Miyamoto T, Nagafuji K, Akashi K et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996;87:4789-4796.
74. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000;97:7521-7526.
75. Jan M, Snyder T, Corces-Zimmerman M et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012;4: 149-118.
76. Fialkow PJ, Martin PJ, Najfeld V et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981;58:158-163.
77. Ferraris AM, Raskind WH, Bjornson BH et al. Heterogeneity of B cell involvement in acute nonlymphocytic leukemia. Blood 1985;66: 342-344.
78. Fialkow PJ, Singer JW, Raskind WH et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987;317:468-473.
79. Fialkow PJ, Janssen JW, Bartram CR. Clonal remissions in acute nonlymphocytic leukemia: Evidence for a multistep pathogenesis of the malignancy. Blood 1991;77:1415-1417.
80. Chomel JC, Brizard F, Veinstein A et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000;95: 404-408.
81. Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-510.
82. Welch JS, Ley TJ, Link DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-278.
83. Majeti R, Becker MW, Tian Q et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009;106:3396-3401.
84. Saito Y, Kitamura H, Hijikata A et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010;2:17ra9.
85. Gentles AJ, Plevritis SK, Majeti R et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010;304: 2706-2715.
86. Sarry JE, Murphy K, Perry R et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R c-deficient mice. J Clin Invest 2011;121:384-395.
87. Barreyro L, Will B, Bartholdy B et al. Overexpression of interleukin 1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012;120:1290-1298.
88. Haase D, Feuring-Buske M, Konemann S et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34 subpopulations. Blood 1995;86: 2906-2912.
89. Mehrotra B, George TI, Kavanau K et al. Cytogenetically aberrant cells in the stem cell compartment (CD34 lin-) in acute myeloid leukemia. Blood 1995;86:1139-1147.
90. Nilsson L, Astrand-Grundstrom I, Arvidsson I et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: Evidence for involvement at the hematopoietic stem cell level. Blood 2000;96:2012-2021.
91. Nilsson L, Astrand-Grundstrom I, Anderson K et al. Involvement and functional impairment of the CD34()CD38(-)Thy-1() hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002;100: 259-267.
92. Will B, Zhou L, Vogler T et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012;120:2076-2086.
93. Busque L, Patel JP, Figueroa ME et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012.
94. Eppert K, Takenaka K, Lechman ER et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086-1093.
95. van Rhenen A, Feller N, Kelder A et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11:6520-6527.
96. Pearce DJ, Taussig D, Zibara K et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 2006;107:1166-1173.
97. Terwijn M, Kelder A, Snel AN et al. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol 2012;34:432-441.
98. Tehranchi R, Woll PS, Anderson K et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010; 363:1025-1037.
99. Zipursky A. Transient leukaemia: A benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003;120:930-938.
100. Wong KY, Jones MM, Srivastava AK et al. Transient myeloproliferative disorder and acute nonlymphoblastic leukemia in Down syndrome. J Pediatr 1988;112:18-22.
101. Roy A, Roberts I, Norton A et al. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: A multi-step model of myeloid leukaemogenesis. Br J Haematol 2009; 147:3-12.
102. Gregory JJ, Jr., Wagner JE, Verlander PC et al. Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA 2001;98:2532-2537.
103. Li J, Sejas DP, Zhang X et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest 2007;117:3283-3295.
104. Ceccaldi R, Briot D, Larghero J et al. Spontaneous abrogation of the G(2)DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest 2011;121:184-194.